The Metastatic Prostate Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Prostate Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Prostate Cancer and features dormant and discontinued products.

GlobalData tracks 70 drugs in development for Metastatic Prostate Cancer by 64 companies/universities/institutes. The top development phase for Metastatic Prostate Cancer is phase i with 26 drugs in that stage. The Metastatic Prostate Cancer pipeline has 62 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Metastatic Prostate Cancer pipeline products market are: Advanced Accelerator Applications, Luye Pharma Group and Bristol-Myers Squibb.

The key targets in the Metastatic Prostate Cancer pipeline products market include Gonadotropin Releasing Hormone Receptor (GNRHR), Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).

The key mechanisms of action in the Metastatic Prostate Cancer pipeline product include Cytotoxic To Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) with eight drugs in Phase II. The Metastatic Prostate Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and 11 key molecule types in the Metastatic Prostate Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Metastatic Prostate Cancer overview

Metastatic prostate cancer occurs when cancerous cells from the prostate gland spread via the bloodstream or lymphatic system to distant sites, especially the bones (such as the spine, pelvis, or hips), lymph nodes, liver, lungs, and other organs. It’s considered an advanced stage of prostate cancer and can present challenges in treatment and management. Metastatic prostate cancer can cause various symptoms depending on the organs affected, including bone pain (often in the spine, hips, or ribs), urinary problems, erectile dysfunction, weakness or numbness in the legs or feet, weight loss, and fatigue.

For a complete picture of Metastatic Prostate Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.